3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Supratentorial Neoplasms
1
Pituitary Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Cysts
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Myofibroma
1
Melanoma
1
Lung Neoplasms
1
Hepatic Tumor Resection
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholecystitis
1
Adenocarcinoma
1
Interventions
Fluorouracil
128
Leucovorin
120
Oxaliplatin
101
Irinotecan
89
Bevacizumab
55
Cetuximab
44
Capecitabine
40
Folfox protocol
29
Panitumumab
22
Colonoscopy
17
Chemotherapy, Adjuvant
16
Floxuridine
15
Early Intervention, Educational
15
Erlotinib Hydrochloride
13
Surveys and Questionnaires
11
IFL protocol
11
Counseling
11
Celecoxib
11
Immunohistochemistry
10
Gemcitabine
10
Psychiatric Rehabilitation
9
Methods
8
Magnetic Resonance Spectroscopy
8
Gene Expression Profiling
8
Exercise
8
Dexamethasone
8
sargramostim
7
Sorafenib
7
Radiotherapy
7
Nivolumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Colonic Neoplasms
×
Desflurane
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled